Newsroom

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will demonstrate smart building and smart city technologies at an innovation and research district being developed in the Berlin TXL project at the former Tegel Airport in Berlin, Germany on September 1. Using a legacy building at the Urban Tech Republic, the demonstration aims to improve energy efficiency, thermal comfort and operational efficiency, and also explore the potential for optimized energy...

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will present its carbon dioxide capture and utilization (CCU) and carbon dioxide removal (CDR) initiatives at Carbon Capture Technology World Expo 2026 at Hamburg Messe in Germany from October 20 to 22. The company’s first-ever exhibit at this Expo will be located in Booth 4B40, Hall B4L and will feature panel displays and video presentations themed “Beyond Carbon Neutrality: Towards Net-Negative Emiss...

TOKYO--(BUSINESS WIRE)--Wolters Kluwer, a global provider of world-class solutions in corporate performance management and Dentsu Soken Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Hirohisa Iwamoto; hereinafter “Dentsu Soken”), today announced that Daihatsu Motor Co., Ltd. (Headquarters: Ikeda City, Osaka; hereinafter “Daihatsu”) has selected CCH Tagetik Intelligent Platform, Wolters Kluwer’s CPM (Corporate Performance Management) solution, as its new budget management system. Dents...

TOKYO--(BUSINESS WIRE)--Wolters Kluwer, a global provider of world-class solutions in corporate performance management and Dentsu Soken Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Hirohisa Iwamoto; hereinafter “Dentsu Soken”), today announced that Daihatsu Motor Co., Ltd. (Headquarters: Ikeda City, Osaka; hereinafter “Daihatsu”) has selected CCH Tagetik Intelligent Platform, Wolters Kluwer’s CPM (Corporate Performance Management) solution, as its new budget management system. Dents...

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, will host the LoRa® Global Ecosystem Forum at the 2026 International Internet of Things Exhibition (IOTE), taking place at the Shenzhen World Exhibition & Convention Center (Bao’an District) from Aug. 26-28. The company is exhibiting in Hall 10, Booth #10C51. T...

GREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced a strategic collaboration with Daol Investment & Securities to provide eligible Korean investors with cost-effective access to global equities through Daol's platform, supported by IBKR's advanced trading infrastructure. The collaboration highlights Interactive Brokers' strength as a provider of brokerage technology and white-label solutions for introducing brokers worldwide. B...

INCHEON, Corea del Sud--(BUSINESS WIRE)--Celltrion (KRX: 068270) oggi ha annunciato il lancio del dosaggio da 300 mg di Omlyclo® (omalizumab), un trattamento per l'orticaria cronica spontanea e l'asma allergica, in Europa.1 Con l'aggiunta del dosaggio da 300 mg, Celltrion ha ampliato il suo portafoglio di Omlyclo® per includere diversi dosaggi e dispositivi destinati ai pazienti, ai professionisti sanitari e alle strutture sanitarie. A seguito del lancio europeo di Omlyclo® da 75 mg e 150 mg al...

INCHEON, Corea del Sur--(BUSINESS WIRE)--Celltrion (KRX: 068270) acaba de anunciar el lanzamiento en Europa de la dosis de 300 mg de Omlyclo® (omalizumab), tratamiento para la urticaria crónica espontánea y el asma alérgica.1 Con la incorporación de la dosis de 300 mg, Celltrion ha extendido su gama de productos Omlyclo® para poder ofrecer así múltiples dosis y formatos de dispositivos a pacientes, profesionales sanitarios e instituciones sanitarias. Después de la presentación en Europa de Omly...

INCHEON, Südkorea--(BUSINESS WIRE)--Celltrion (KRX: 068270) gab heute die Markteinführung der 300-mg-Dosierung von Omlyclo® (Omalizumab), einem Medikament zur Behandlung von chronischer spontaner Urtikaria und allergischem Asthma, in Europa bekannt.1 Mit der Einführung der 300-mg-Dosierung hat Celltrion sein Omlyclo®-Portfolio um verschiedene Dosierungen und Darreichungsformen für Patienten, medizinisches Fachpersonal und Gesundheitseinrichtungen erweitert. Nach der Markteinführung von Omlyclo®...

INCHEON, Corée du Sud--(BUSINESS WIRE)--Celltrion (KRX : 068270) a annoncé aujourd’hui le lancement en Europe de la dosologie de 300 mg d’Omlyclo® (omalizumab), un traitement contre l’urticaire chronique spontanée et l’asthme allergique.1 Avec l’ajout de cette dosologie de 300 mg, Celltrion a élargi sa gamme Omlyclo® afin d’inclure plusieurs dosages et formats de conditionnement destinés aux patients, aux professionnels de santé et aux établissements de soins. Après le lancement européen d’Omly...